More than 30 abstracts evaluating Keytruda, Merck's anti-PD-1 therapy, in combination with other cancer therapies and as monotherapy, will be presented.
Key data to be presented in non-small cell lung cancer (NSCLC) include new pooled findings from three trials KEYNOTE-189, KEYNOTE-407 and KEYNOTE-021 (cohort G), evaluating Keytruda in combination with chemotherapy among a subgroup of patients whose tumors do not express PD-L1.
Three-year overall survival data with Keytruda monotherapy from KEYNOTE-024 will also be presented and was selected for inclusion in the official WCLC press programme.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review